- Home
- EFSH vs NCNA Comparison
EFSH vs NCNA Comparison
Compare EFSH & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSH
- NCNA
- Stock Information
- Founded
- EFSH 1948
- NCNA 1997
- Country
- EFSH United States
- NCNA United Kingdom
- Employees
- EFSH N/A
- NCNA N/A
- Industry
- EFSH Professional Services
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- EFSH Consumer Discretionary
- NCNA Health Care
- Exchange
- EFSH Nasdaq
- NCNA Nasdaq
- Market Cap
- EFSH 4.2M
- NCNA 4.3M
- IPO Year
- EFSH N/A
- NCNA 2017
- Fundamental
- Price
- EFSH $0.23
- NCNA $1.14
- Analyst Decision
- EFSH
- NCNA Buy
- Analyst Count
- EFSH 0
- NCNA 2
- Target Price
- EFSH N/A
- NCNA $25.00
- AVG Volume (30 Days)
- EFSH 3.9M
- NCNA 238.3K
- Earning Date
- EFSH 11-19-2024
- NCNA 11-25-2024
- Dividend Yield
- EFSH N/A
- NCNA N/A
- EPS Growth
- EFSH N/A
- NCNA N/A
- EPS
- EFSH N/A
- NCNA N/A
- Revenue
- EFSH $69,415,140.00
- NCNA N/A
- Revenue This Year
- EFSH N/A
- NCNA N/A
- Revenue Next Year
- EFSH N/A
- NCNA N/A
- P/E Ratio
- EFSH N/A
- NCNA N/A
- Revenue Growth
- EFSH 228.22
- NCNA N/A
- 52 Week Low
- EFSH $0.20
- NCNA $0.96
- 52 Week High
- EFSH $820.95
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- EFSH 39.61
- NCNA 43.15
- Support Level
- EFSH $0.22
- NCNA $0.96
- Resistance Level
- EFSH $0.32
- NCNA $1.37
- Average True Range (ATR)
- EFSH 0.04
- NCNA 0.15
- MACD
- EFSH 0.22
- NCNA -0.00
- Stochastic Oscillator
- EFSH 15.83
- NCNA 26.09
About EFSH 1847 Holdings LLC
1847 Holdings LLC is a diversified holding company. It operates in Four segments: Retail and appliances, Retail and Eyewear, Construction, and Automotive Supplies. The company generates maximum revenue from the Construction segment. The firm, through its subsidiaries, provides a wide range of land application services and sells equipment and parts, primarily to the agricultural, construction, and lawn and garden industries.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.